BIIB$161.48
$161.61
Chart
Performance
Key Stats
AI BIIB Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyBiogen demonstrates solid fundamental strength with consistent earnings and a healthy balance sheet. Thematic exposure to neurological disorders is a positive, though current technicals suggest a neutral to cautious short-term outlook.
Thematic
Biogen is strategically positioned in the growing neuroscience market, driven by an aging global population and increasing demand for treatments for neurological diseases. Its product pipeline and biosimilar offerings contribute to its thematic appeal.
Fundamental
Biogen exhibits strong profitability, evidenced by its consistent earnings per share and healthy net margins. Its balance sheet is robust, with manageable debt levels and significant cash reserves.
Technical
Biogen's stock price is currently trading within a range, with mixed signals from technical indicators. While some moving averages suggest a potential uptrend, momentum indicators are mixed, indicating a period of consolidation or indecision.
| Factor | Score |
|---|---|
| Neuroscience Market Growth | 90 |
| Alzheimer's Disease Potential | 70 |
| Biosimilar Market Entry | 75 |
| R&D Investment | 80 |
| Competition | 65 |
| Factor | Score |
|---|---|
| Valuation | 75 |
| Profitability | 85 |
| Growth | 55 |
| Balance Sheet Health | 80 |
| Cash Flow | 88 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 65 |
| Volume Confirmation | 70 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Surprises
Biogen Inc. (BIIB) has demonstrated a pattern of beating earnings per share (EPS) estimates, with positive surprises in the last 8 reported quarters, indicating reliable earnings performance.
Attractive P/E Ratio
The Price-to-Earnings (P/E) ratio of 13.10 (TTM) is relatively low compared to historical performance and the broader biotechnology sector, suggesting potential undervaluation.
Bearish Points (7)
High Quarterly P/E Ratio
The Price-to-Earnings (P/E) ratio for Q1 2025 is exceptionally high at 83.4, indicating that the market is pricing in very high future growth expectations that may be difficult to sustain.
Slowing Revenue Growth
Annual revenue has been on a downward trend from $10.98 billion in 2021 to $9.68 billion in 2024, signaling potential challenges in top-line expansion.
Calendar
July 2025
31
Next Earnings Date
H: $4.12
A: $3.88
L: $3.59
H: 2.41B
A: 2.32B
L: 2.24B
Profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
170.67 USD
The 39 analysts offering 1 year price forecasts for BIIB have a max estimate of 260.00 and a min estimate of 115.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Co-developer and commercialization partner with Biogen for Leqembi (lecanemab), a key Alzheimer's disease treatment, making them highly interdependent in this critical therapeutic area.
Weight: 98
Long-standing strategic collaboration partner with Biogen, co-developing and commercializing Spinraza (nusinersen) for Spinal Muscular Atrophy (SMA), and progressing multiple other neurological assets in pipeline.
Weight: 95
Direct competitor in the Alzheimer's disease market with its amyloid-targeting therapy, Donanemab, offering a similar mechanism of action to Biogen's Leqembi.
Weight: 93
Major competitor in Multiple Sclerosis (MS) with Ocrevus, a leading therapy competing directly with Biogen's MS portfolio (Tysabri, Tecfidera), and also has an Alzheimer's pipeline.